Correction to: Patients’ usability of seven most used dry-powder inhalers in COPD

Correction to: Patients’ usability of seven most used dry-powder inhalers in COPD

Authors

  • Roberto W. Dal Negro National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology, Verona
  • Paola Turco Research and Clinical Governance, Verona
  • Massimiliano Povero AdRes Health Economics and Outcome Research, Torino

Keywords:

Dry powder inhalers, COPD, Global usability score, Inhalation therapy, Usability

Abstract

Correction to: Multidiscip RespirMed (2019) 14:30 https://doi.org/10.1186/s40248-019-0192-5

After publication of the Original research article [1] it was brought to our attention that the sentence at the bottom of the section entitled Discussion (pag 6 of 9, just below Fig. 4) must be corrected as follows: “In real life, DPIs are highly prescribed in Italian COPD patients being their prescription usually independent of their known basic characteristics and technical differences, such as the different number of main actions required for their actuation (7 for Breezhaler, 4 for Turbohaler, and 3 for the remaining devices),” and their intrinsic resistance, ranging from 0.017 kPa0.5 L/min to 0.039 kPa0 .5 L/min [28, 29].

Downloads

Published

21-10-2019

Issue

Section

Correction

How to Cite

1.
Dal Negro RW, Turco P, Povero M. Correction to: Patients’ usability of seven most used dry-powder inhalers in COPD. Multidiscip Respir Med [Internet]. 2019 Oct. 21 [cited 2024 Jul. 4];14(1). Available from: https://mrmjournal.org/index.php/mrm/article/view/65